Table 5.

Cancer treatment alterations and complications stratified by IBD activity at cancer diagnosis.

Variable	IBD inactive at cancer diagnosis (n=400, 89.5%)	IBD active at cancer diagnosis (n=47, 10.5%)	p-value
Patients with data for cancer treatment alteration	176 (44.0%)	15 (31.9%)	-
Any treatment alteration	22 (12.5%)	2 (13.3%)	0.720
Dose modification	10 (5.7%)	1 (6.7%)	0.957
Reasons noted	Neuropathy, diarrhea	Diarrhea
Treatment delay	10 (5.7%)	2 (13.3%)	0.401
Reasons noted	Neuropathy, diarrhea	Diarrhea
Treatment discontinuation	19 (25.0%)	2 (13.3%)	0.717
Reasons noted	Venous thromboembolism, neuropathy, diarrhea, fracture, rash	Diarrhea
Patients with data for hospitalization during cancer treatment	334 (83.5%)	42 (89.4%)	-
Hospitalization during cancer treatment	59 (17.7%)	17 (40.5%)	0.001
Reasons noted	Venous thromboembolism, diarrhea, fracture, sepsis	Diarrhea, sepsis